Back to Search

MARIEL SMITH, MD

MD

Pediatric Hematology & Oncology Physician

NPI: 1659637841Individual

Specialties, Licenses & Credentials

Student in an Organized Health Care Education/Training Program

Student in an Organized Health Care Education/Training Program

Code: 390200000X

Pediatric Hematology & Oncology PhysicianPrimary

Pediatrics — Pediatric Hematology-Oncology

Code: 2080P0207X

281236(MA)

Research & Publications (20)

Indirect regulation of presenilins in CREB-mediated transcription.
PMID 19289467·J Biol Chem·2009
7-preclinical
Denosumab in men receiving androgen-deprivation therapy for prostate cancer.
PMID 19671656·N Engl J Med·2009
4-observational
Treatment-related diabetes and cardiovascular disease in prostate cancer survivors.
PMID 18790986·Ann Oncol·2008
6-review
Toremifene increases bone mineral density in men receiving androgen deprivation therapy for prostate cancer: interim analysis of a multicenter phase 3 clinical study.
PMID 18001802·J Urol·2008
3-trial
Adipocytokines, obesity, and insulin resistance during combined androgen blockade for prostate cancer.
PMID 18308111·Urology·2008
8-other
Metabolic changes during gonadotropin-releasing hormone agonist therapy for prostate cancer: differences from the classic metabolic syndrome.
PMID 18348297·Cancer·2008
8-other
Toremifene improves lipid profiles in men receiving androgen-deprivation therapy for prostate cancer: interim analysis of a multicenter phase III study.
PMID 18398147·J Clin Oncol·2008
3-trial
Gonadotrophin-releasing hormone agonists, diabetes and cardiovascular disease in men with prostate cancer: which metabolic syndrome?
PMID 18454791·BJU Int·2008
8-other
Androgen deprivation therapy and risk for diabetes and cardiovascular disease in prostate cancer survivors.
PMID 18765113·Curr Urol Rep·2008
6-review
Diabetes and mortality in men with locally advanced prostate cancer: RTOG 92-02.
PMID 18779620·J Clin Oncol·2008
2-rct
Androgen deprivation therapy for prostate cancer: new concepts and concerns.
PMID 17940447·Curr Opin Endocrinol Diabetes Obes·2007
6-review
Predictors of skeletal complications in men with hormone-refractory metastatic prostate cancer.
PMID 17826496·Urology·2007
4-observational
Obesity and sex steroids during gonadotropin-releasing hormone agonist treatment for prostate cancer.
PMID 17200361·Clin Cancer Res·2007
8-other
Insulin sensitivity during combined androgen blockade for prostate cancer.
PMID 16434464·J Clin Endocrinol Metab·2006
8-other
Celecoxib versus placebo for men with prostate cancer and a rising serum prostate-specific antigen after radical prostatectomy and/or radiation therapy.
PMID 16782912·J Clin Oncol·2006
2-rct
Treatment-related osteoporosis in men with prostate cancer.
PMID 17062721·Clin Cancer Res·2006
6-review
Risk of clinical fractures after gonadotropin-releasing hormone agonist therapy for prostate cancer.
PMID 16406890·J Urol·2006
8-other
Markers of bone metabolism in prostate cancer.
PMID 16680835·Cancer Treat Rev·2006
6-review
Gonadotropin-releasing hormone agonists and fracture risk: a claims-based cohort study of men with nonmetastatic prostate cancer.
PMID 16258089·J Clin Oncol·2005
8-other
Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer.
PMID 15860850·J Clin Oncol·2005
3-trial

Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.

Contact & Hours

Via practice · 2 locations total

Address
55 FRUIT ST
BOSTON, MA 02114

Locations (2)

Practice Location

55 FRUIT ST, BOSTON, MA
(617) 726-2737

Practice Location

525 E 68TH ST, NEW YORK, NY
(212) 746-3131

Quick Facts

NPI
1659637841
Entity Type
Individual
Gender
Female
Medicare
Not confirmed
Specialties
2
Locations
2
Publications
20

Are you this provider?

Claim Your Profile